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INTRODUCTION
The early spread of tumor cells among breast cancer patients 
is usually undetectable, even by conventional pathologic analy-
ses and high-resolution imaging technologies. With highly 
sensitive immunocytochemical and molecular assays, it is pos-
sible to detect occult metastatic tumor cells at the single-cell 
stage in peripheral blood, regional lymphatic nodes, and bone 
marrow before incurable distant metastases occur.1 Circulat-
ing tumor cells (CTCs) circulate in the peripheral blood of pa-
tients. CTCs can originate from both the primary tumor and its 
metastases. It is believed that CTCs mediate the hematogenic 
spread of cancer to distant organs, including bone, lung, brain, 
and liver. CTCs have potential to form metastases, and for this 
reason, they can be useful predictors of poor outcomes, such 
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as shorter disease-free and overall survival.2-4 Furthermore, 
checking CTC levels may be valuable for follow-up evaluation 
and to monitor therapeutic efficacy.1,5-7
Immunocytochemistry using antibodies against proteins, 
which are not expressed in mesenchymal cells, but in epithe-
lial cells, is commonly used for the detection of CTCs. In recent 
studies, reverse transcriptase polymerase chain reaction (RT-
PCR) and quantitative real-time RT-PCR methods have shown 
higher diagnostic sensitivity.8-10 The development of real-time 
RT-PCR technology has allowed an enormous progress in can-
cer diagnostics, providing significant and quantitative data 
about gene expression in an automated, fast, flexible, afford-
able, and cost-effective way. Real-time RT-PCR has recently 
been used to detect CTCs in the peripheral blood and lymph 
nodes in patients with metastatic breast cancer through the 
detection of differential expression of marker genes, which are 
achieved by multigene RT-PCR assays, respectively.10,11
In this study, we report an adaptation and analytical valida-
tion of a real-time quantitative RT-PCR methodology for cyto-
keratin (CK)-19 mRNA using the LightCycler system.8,12 CK-19 
is a typical epithelial marker, which is present in epithelial cells, 
but is not found in mesenchymal cells. It has been investigat-
ed extensively as a potential marker to detect CTCs in early 
and metastatic breast cancer.3,10,13-24 Among the numerous mo-
lecular markers currently being used to detect occult micro-
metastasis indirectly in patients with breast cancer, detecting 
CK-19 mRNA expression is considered one of the most prom-
ising methods to detect CTCs, due to its high sensitivity and 
specificity.11
 
MATERIALS AND METHODS
Cell samples
The human breast cancer cell lines including MCF-7, SK-BR-3, 
and MDA-MB-231 (obtained from the Korean Cell Line Bank, 
Seoul, Korea), which contain the CK-19 gene, were used as pos-
itive controls. Each of the cell lines was cultured in Dulbecco’s 
modified eagle medium containing 10% fetal bovine serum, 
100 U/mL penicillin, and 100 μg/mL streptomycin (HyClone, 
Logan, UT, USA).
Patients and blood samples
From October 2010 until February 2012, a total of 242 consecu-
tive patients with breast cancer (median age 53 years, 26–83 
years), including 69 patients with early breast cancer (stage I–II, 
28.5%), 47 patients with locally advanced breast cancer (19.4%), 
and 126 patients with metastatic disease (stage IV, 52.1%), 
were enrolled to identify detection rates of CTCs according to 
tumor burden. To evaluate clinical relevance, blood samples 
were collected after surgery or before adjuvant therapy in early 
breast cancer patients, at initial diagnosis in locally advanced 
breast cancer patients and at implementation of therapy or the 
regimen change for disease progression in metastatic patients. 
All patients with locally advanced breast cancer received neo-
adjuvant chemotherapy before surgery.
To serve as controls, 30 healthy female donors were recruit-
ed (median age 47 years, 30–54 years) and blood samples were 
obtained. Peripheral blood (12.5 mL in ethylenediaminetet-
raacetic acid) was obtained from healthy volunteers and 
breast cancer patients. The blood samples were conditioned at 
4°C for different time intervals and processed within a maxi-
mum of 24 hours after the samples were drawn. To avoid epi-
thelial contamination by the skin, the first 5 mL of each blood 
sample was discarded. Prior to participation in this study, pa-
tients and healthy donors provided informed consent, ap-
proved by the Ethics and Scientific Committees of our institu-
tion (IRB ID number=4-2011-0011).
Total RNA isolation and cDNA synthesis
Isolation of total RNA was processed using the Trizol LS re-
agent (Gibco-BRL, Carlsbad, CA, USA) according to the man-
ufacturer’s instructions. All RNA preparation and handling 
procedures were performed in a laminar flow hood under 
RNase-free conditions. Isolated RNA was dissolved in RNA 
storage buffer (Life Technologies, Carlsbad, CA, USA) and 
stored at -80°C for further processing. The RNA concentration 
was evaluated by absorbance readings at 260 nm using a Nano-
Drop spectrophotometer (Thermo Scientific, Fremont, CA, 
USA). RNA integrity was tested by PCR amplification of the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) house-
keeping gene. Reverse transcription of RNA was carried out 
with the Omniscript Reverse Transcription RT kit (QIAGEN, 
Hilden, Germany). Total RNA prepared from the MCF-7 cell 
line was used as a positive control. cDNA was synthesized from 
5 μg of total RNA isolated from peripheral blood mononuclear 
cells of healthy donors and breast cancer patients, according 
to the manufacturer’s instructions.
Real-time RT-PCR amplification
Quantification is based on real-time monitoring during PCR of 
fluorescently labeled specific probes for CK-19. Real-time RT-
PCR for CK-19 mRNA was performed using the LightCycler 
system 480 (Roche, Penzberg, Upper Bavaria, Germany). Real-
time RT-PCR was conducted in a total volume of 20 μL, con-
taining 2 μL of cDNA, 0.3 μg of the CK-19 forward primer (10 
pM), 0.3 μL of the reverse primer CK-19 (10 pM), 0.3 μL of the 
probe CK-19 (10 pM), and 10 μL of LightCycler 480 Probes Mas-
ter mix reagent (2X, Roche, Penzberg, Upper Bavaria, Germa-
ny). Finally, diethylpyrocarbonate (DEPC)-H2O was added to 
the reaction mix. All primers and hybridization probe sequenc-
es are listed in Table 1. 
PCR reaction was initiated after a 10-minute denaturation at 
95°C, and then the cycling protocol, consisting of denaturation 
at 95°C for 10 seconds, and annealing at 60°C for 30 seconds, 
was repeated 50 times. Fluorescence detection was performed 
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at the end of each annealing step for 0.25 second. 
For quantification, an external standard curve was applied 
using cDNA from MCF-7 cells, which was described in previ-
ous studies.8,12 Total RNA was obtained from 1×106 MCF-7 cells 
through serial dilution.8,12 This cDNA was used as the CK-19-pos-
itive control. This standard curve was created by plotting the 
number of MCF-7 cells corresponding to each value of its Ct.8,12 
The proposed real-time RT-PCR methodology was applied 
in a total of 272 peripheral blood samples collected from 30 
healthy female donors, 69 patients with early breast cancer af-
ter surgery or before adjuvant therapy, 47 patients with locally 
advanced breast cancer, and 126 patients with verified metas-
tasis before regimen change or first-line chemotherapy. 
The amount of total RNA in each sample was used to nor-
malize our real-time RT-PCR data. We adopted the previous de-
tection limit method to set up the cutoff of CTC detection.8 The 
presence of ≥0.792 MCF-7 cell equivalents/5 μg RNA in the 
patient blood sample was considered a positive result on the 
basis of the analytical detection limit. According to this cutoff, the 
specificity of the proposed method was evaluated by analyz-
ing peripheral blood samples from 30 female healthy donors.
Primary data analysis
Real-time RT-PCR data was quantified as Ct values that are 
inversely related to the amount of starting template: high Ct val-
ues were correlated with low levels of gene expression, where-
as low Ct values were correlated with high levels of gene expres-
sion. Results were normalized to an internal control reference 
gene. If the mean Ct value for CK-19 mRNA was higher or equal 
to 36, the CK-19 expression was considered undetectable. To 
define the baseline levels of CK-19 expression and thresholds 
for CK-19 positivity, 30 specimens of peripheral blood mono-
nuclear cells obtained from female healthy donors with no 
evidence of malignancy were analyzed. The molecular analy-
sis was blinded to clinical outcome and patient clinicopatho-
logical data.
Tumor stage was based on the American Joint Committee on 
Cancer Staging manual 6th edition. Histological grade was as-
sessed based on the modified Bloom-Richardson classification. 
Tumors with ≥1% nuclear-stained cells were considered to 
have estrogen receptor (ER) and progesterone receptor (PR) 
positivity. Human epidermal growth factor receptor (HER2) 
overexpression was considered positive in cases with an im-
munohistochemistry (IHC) score of 3+ or gene amplification 
by fluorescence in situ hybridization with an IHC score of 2+.25 
Breast cancer subtypes, based on ER, PR, and HER2, were cat-
egorized into three subtypes: those that were ER- and/or PR-
positive were classified as the luminal subtype; those that were 
ER- and PR-negative and HER2-positive were classified as the 
HER2 subtype; and those that were negative for all markers 
were classified as triple-negative breast cancer.
Statistical analysis
SPSS version 20.0 (IBM, Armonk, NY, USA) statistical software 
was used for the analysis of pathological and molecular out-
come. Chi-square tests were conducted to explore the associa-
tion between pre-defined baseline categorical covariates and 
real-time RT-PCR positivity/negativity status. t-test or ANOVA 
was used to compare continuous variables. Pre-defined base-
line covariates were age, TNM stage, histological grade, ER sta-
tus, PR status, and HER2 status. Statistical significance was de-
fined as p values<0.05. All tests were two-sided. 
RESULTS
Detection rates
The real-time RT-PCR method based on CK-19 mRNA showed 
Table 1. Sequences of Primers and Hybridization Probes Used in This Study 
mRNA Product size (bp) Primer 5'- 3' Probe 5'-3'
CK-19a 96 GAT GAG CAG CTC CGA GGT TA TCT TCC AAG GCA GCT TTC AT CTG CGG CGC CCC TTC GTC T 
CK-19b 141 CGG GAC AAG ATT CTT GGT CGT TGA TGT CGG CCT CCA TGT CCT GCA GAT CGA CAA CGC CC 
CK-19c 127 ATG AAA GCT GCC TTG GAA GA GCT CAC TAT CAG CTC GCA CA ATC AGC GGT ATT GAA GCC C 
GAPDH 150 CCA TCT TCC AGG AGC GAG ATC G ATG GTG GTG AAG ACG CCA GTG TCC ACG ACG TAC TCA GCG CCA GCA 
CK, cytokeratin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Fig. 1. Ct values according to treatment setting in patients with CTCs. High 
Ct values correlated with low levels of gene expression, whereas low Ct 
values correlate with high levels of gene expression. The box plots repre-
sent the median, maximal, and minimal number of Ct values. There was 
no significant difference in terms of Ct values among three groups 
(p=0.16). CTC, circulating tumor cell; EBC, early breast cancer; LBC, locally 
advanced breast cancer; MBC, metastatic breast cancer.
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100% specificity, because none of the 30 blood samples from 
healthy donors had detectable CK-19 mRNA positive cells. 
In 69 patients with early breast cancer, CK-19 mRNA positive 
cells were detected in 33 patients (47.8%). Among the 47 pa-
tients with locally advanced breast cancer, 22 (46.8%) patients 
were found to be positive prior to neoadjuvant chemotherapy. 
CK-19 mRNA positive cells were detected in 77 (61.1%) patients 
among the 126 patients with distant metastasis. The Ct values 
observed in patients with breast cancer who had detectable 
CK-19 mRNA, classified according to treatment groups, are il-
lustrated in Fig. 1. There was no significant difference in terms of 
Ct values according to the treatment group (p=0.164) (Fig. 1).
Patient characteristics 
The mean age of all patents was 52.1±10.4 years. Mean ages 
according to tumor burden were 53.1±9.7 years in patients with 
early breast cancer, 50.1±11.4 years in patients with locally ad-
vanced cancer, and 52.3±10.4 years in patients with distant 
metastasis. There were no significant differences in age accord-
ing to tumor burden.
The distribution of patient demographic and clinicopatho-
logical characteristics is shown in Table 2. The rates of CTC-
positive cells were not different between patients younger than 
50 years and those aged 50 years and older. Patients with dis-
tant metastasis had a CTC detection rate of 61.1% in their blood 
samples; meanwhile, patients with early and locally advanced 
breast cancer had detection rates of 47.8% and 46.8%, respec-
tively. CTCs were more often observed in ER-negative tumors 
than in ER-positive tumors (60.8% vs. 51.0%, respectively). In 
terms of breast cancer subtypes, CTCs were more commonly 
detected in patients with TNBC than other subtypes (63.3% vs. 
47.5–55.0%). All clinicopathological features were not signifi-
cantly associated with the detection of CTCs, as defined by 
CK-19 mRNA positive cells (Table 2). 
Table 2. Patient Demographics according to the Detection of CTCs, Defined as CK-19 mRNA-Positive Cells
CTC
p valueNegative Positive
Count, n Row, % Count, n Row, %
Age 50 0.248
<50 39 41.1 56 58.9
≥50 71 48.6 75 51.4
Tumor burden 0.101
Early 36 52.2 33 47.8
Metastatic 49 38.9 77 61.1
Locally advanced 25 53.2 22 46.8
Stage 0.162
I 21 55.3 17 44.7
II 11 45.8 13 54.2
III 28 53.8 24 46.2
IV 49 38.9 77 61.1
Grade 0.931
I 11 50.0 11 50.0
II 25 54.3 21 45.7
III 17 54.8 14 45.2
ER 0.154
Negative 31 39.2 48 60.8
Positive 77 49.0 80 51.0
PR 0.577
Negative 53 43.8 68 56.2
Positive 55 47.4 61 52.6
HER2 0.289
Negative 78 43.8 100 56.2
Overexpression 32 51.6 30 48.4
Subtype 0.259
Luminal 59 45.0 72 55.0
HER2 31 52.5 28 47.5
TNBC 18 36.7 31 63.3
CTC, circulating tumor cell; CK, cytokeratin; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; TNBC, triple-nega-
tive breast cancer.
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Table 3 shows the detection rates of CK-19 mRNA-positive 
cells according to metastatic sites in patients with distant me-
tastasis. CTCs were more frequently identified in patients with 
visceral metastasis than in those with non-visceral metastasis 
(61.5% vs. 58.6%); however, this difference was not significant 
(p=0.784). Patients with pleural metastasis demonstrated sig-
nificantly higher CTC detection than those without pleural me-
tastasis (p=0.04) All other metastatic sites were not associated 
with CK-19 mRNA-positive CTCs. 
Overall survival according to CK-19 mRNA-positive 
CTCs
Overall survival curves according to CK-19 mRNA-positive 
cells are shown in Fig. 2. With a median follow-up period of 29 
months (range, 0–44 months), survival was poorer in patients 
positive for CTCs than in those without detectable CTCs, and 
the difference was significant (p=0.014). In multivariate analy-
sis adjusting for age, CTC detection, and tumor burden, only 
metastatic tumor burden was significantly associated with 
overall survival [p<0.001, hazard ratio (HR)=27.014, 95% con-
fidence interval (CI)=8.524–85.617]. Binary CTC detection (yes 
or no) was not a significant prognostic factor for overall survival 
in multivariate analysis (p= 0.097, HR=0.700, 95% CI=0.459–
1.067) (Table 4).
DISCUSSION
CTCs are epithelial tumor cells detected in the peripheral blood 
of patients with solid tumors using mainly immunocytochemi-
cal approaches including CellSearch (Veridex LLC, Raritan, 
NJ, USA) and AdnaTest (AdnaGen AG, Langenhagen, Germa-
Table 3. Metastatic Sites according to the Detection of CTCs, Defined as CK-19 mRNA-Positive Cells
CTC
p valueNegative Positive
Count, n Column, % Count, n Column, %
Visceral 0.784
Visceral 37 38.5 59 61.5
Non-visceral 12 41.4 17 58.6
Bone 0.320
Negative 22 45.8 28 36.8
Positive 26 54.2 48 63.2
Lung 0.444
Negative 26 53.1 35 46.1
Positive 23 46.9 41 53.9
Pleural 0.045
Negative 39 81.2 49 64.5
Positive 9 18.8 27 35.5
Liver 0.945
Negative 30 61.2 47 61.8
Positive 19 38.8 29 38.2
Brain 0.947
Negative 35 72.9 55 72.4
Positive 13 27.1 21 27.6
Soft Tissue 0.749
Negative 25 51.0 41 53.9
Positive 24 49.0 35 46.1
Other 0.050
Negative 46 93.9 62 81.6
Positive 3 6.1 14 18.4
CTC, circulating tumor cell; CK, cytokeratin.
Table 4. Multivariate Analysis according to the Detection of CTC, De-
fined as CK-19 mRNA-Positive Cells
p value HR
95% CI
Lower Upper
Age (<50 vs. ≥50) 0.315 0.806 0.529 1.227
CTC detection (no vs. yes) 0.097 0.700 0.459 1.067
Tumor burden
Early Ref.
Metastatic <0.001 27.014 8.524 85.617
Locally advanced 0.540 0.493 0.051 4.746
CTC, circulating tumor cell; CK, cytokeratin; HR, hazard ratio; CI, confidence 
interval.
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ny).1,10,26 CellSearch is the only technology for CTC detection 
that has been admitted by the Food and Drug Administration 
as an aid in monitoring patients with metastatic breast, colorec-
tal, and prostate cancers. However, CellSearch has a limitation 
that is inherent in its immunomagnetic enrichment system. 
EpCAM-negative CTCs can be excluded during the test using 
CellSearch, because CellSearch is based on the magnetic de-
tection of EpCAM-positive cells. Some investigators have point-
ed out heterogeneous expression of EpCAM in breast cancer 
and down-regulation of EpCAM after chemotherapy.27 Thus, 
detection systems that use RT-PCR for CK or multiple markers 
that can identify the presence of CTCs, regardless of EpCAM 
expression, have been investigated in several studies.8,12-14,22,24 
Compared to the CellSearch immunomagnetic enrichment 
system, RT-PCR for CK or other multimarkers exhibits superi-
or sensitivity.10 In this study, CK-19 mRNA expression was de-
tected in more than half of patients with metastatic disease and 
about half of patients with early breast cancer, and these re-
sults were similar to those of a previous study.14 The detection 
rate of CTCs using the Cellsearch system was about 20–30% in 
patients with breast cancer.10,28 The detection rate of RT-PCR 
for CK-19 mRNA expression in the current study was almost 
two-fold higher than that of CellSearch. However, there was 
no standardized technique for detecting CK-19 mRNA-posi-
tive CTCs among previous studies that used CK-19 mRNA ex-
pression to report on the presence of CTCs, and considerable 
heterogeneity of detection methods existed in previous stud-
ies.8,11,12 Therefore, caution is required in the interpretation 
and application of RT-PCR for the detection of CK-19 mRNA 
expression.
The relationships observed between the presence of CTCs 
and clinicopathological parameters were different in different 
studies due to heterogeneity of the study design.11,13,14,20,22,23,26 
The meta-analysis conducted by Zhao, et al.11 revealed that 
CTC-positive tumors were associated with biologically aggres-
sive phenotypes; on the other hand, CK-19 mRNA-positive 
breast cancers were not. Several studies also reported no rela-
tion between the presence of CK-19 mRNA-positive CTCs and 
clinicopathological parameters, including age, tumor size, ER, 
PR, HER2, and grade,13,14,20,22,23 and only the tumor burden was 
related to presence of CTCs.13,22 Previous studies reported that 
more CTCs were detected in metastatic disease than in early 
disease.13,22 Our study showed no relationship between the 
presence of CK-19 mRNA-positive CTCs and clinicopathologi-
cal parameters with the exception of pleural metastasis, and 
this is partially concordant with a previous study.29 The lack of 
agreement between the current study and previous studies in 
the literature may be due to the difference in defining CTCs and 
the lack of standardized techniques for RT-PCR of CK-19 mRNA.
The current study demonstrated that patients with CK-19 
mRNA CTC detection showed poorer survival than those with-
out detection in univariate analyses; however, this did not hold 
up on multivariate analyses. Stathopoulou, et al.14 suggested 
that CTC detection by CK-19 mRNA expression is related to 
poor survival. Benoy, et al.22 also reported that elevated CK-19 
in bone marrow is prognostic; however, the peripheral CK-19 
level is not. Although there are some similarities in detection 
techniques between previous and current studies, the prog-
nostic values of CTC detection using CK-19 mRNA expression 
varies among studies. This discordance among studies may 
be due to heterogeneity in the study design: the Greek study 
mainly included metastatic breast cancer,14 whereas the Bel-
gian study enrolled more patients with early breast cancer 
than with metastatic breast cancer.26 We enrolled 129 patients 
with metastatic breast cancer; this constituted about half 
(52.1%) of all patients. These discrepancies among the studies 
may have caused the difference in outcomes. Recently, a large 
prospective multicenter study confirmed that CTC detection 
by the CellSearch system in patients with early breast cancer 
is also clinically relevant and prognostic.28 In the current study, 
it was not possible to analyze patients with early and advanced 
breast cancer using subgroup analyses, due to the short fol-
low-up duration. Therefore, further studies with longer follow-
up periods are needed for the patients with early breast can-
cer in this cohort.
There are some limitations of this study. First, due to the ret-
rospective nature of the study and its sample size, selection bias 
cannot be ruled out. Pleural metastases were frequently found 
in the CTC-positive diseases in the current study. However, 
the cases of pleural metastases were too few to make solid 
conclusions, and thus, further studies are needed. Second, the 
absence of a consensus for CTC definition or threshold using 
RT-PCR methods makes it difficult to apply the results of the 
Fig. 2. Overall survival according to the detection of CTCs defined by CK-
19 mRNA-positive cells. CTC, circulating tumor cell; CK, cytokeratin.
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study to clinical settings. Different definitions and thresholds 
among studies can have an influence on reproducibility of the 
clinical role of CTCs in breast cancer. Third, the sole use of CK-
19 mRNA expression for the detection of CTCs in the current 
study could be a limitation of the study, because the use of a 
single marker for the detection of CTCs may not be solely rep-
resentative of various types of CTCs that may be defined by the 
presence of other CK family proteins, such as CK-8 and -18, and 
because the use of CK-family as CTC markers can enhance 
the detection rate of CTCs.30,31 A previous study indicates that 
RT-PCR for multiple markers, including HER2 and MUC1, 
which are closely related to the progression or development 
of breast cancer, can provide more prognostic or predictive 
information.32 Furthermore, epithelial-messenchymal transi-
tion markers and stem cell markers can increase in CTCs.33 
Therefore, further study using RT-PCR for multiple markers is 
needed to extend our knowledge of CTCs. Finally, recent ge-
nomic, morphological, and cultural analyses including single-
cell sequencing, CTC clusters, and conditionally repro-
grammed cells using CTCs cannot be accessed using RT-PCR 
for CK-19 mRNA-positive CTCs.34-36 Thus, new technology that 
can isolate morphological CTCs has been introduced to over-
come these limitations.37 Further studies using the enhanced 
technology may shed light on the role of complex behaviors of 
CTCs in tumor biology. 
In conclusion, we adapted and validated a detection meth-
od for CTCs using RT-PCR for CK-19 mRNA expression. The 
current study suggested that CTC detection using RT-PCR for 
CK-19 mRNA expression may have a clinical impact on overall 
survival in patients with breast cancer. Even though clinico-
pathological parameters, including age, tumor size, nodal sta-
tus, ER, PR, HER2, and the grade of the primary tumor, which 
are all known prognostic factors of breast cancer, were not re-
lated to CTC detection using RT-PCR for CK-19 mRNA expres-
sion, with the exception of pleural metastasis, breast cancer 
patients in which CTCs were detected showed poor overall 
survival in univariate analysis. Further studies are needed to 
clarify the clinical role of the RT-PCR approach for CTC detec-
tion in the peripheral blood of patients with breast cancer. 
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